Skip to main content
. 2006 Mar;99(3):132–140. doi: 10.1258/jrsm.99.3.132

Table 3.

Raw data for the placebo, diclofenac, ibuprofen and paracetamol controlled trials (secondary analysis)

Study
Celecoxib
Other
OR (95% CI)
Events Total No. subjects Events Total No. subjects
Myocardial infarction
Solomon et al. (Ref 6) 18 1356 3 679 2.67 (0.5 to 8.41)
CLASS (White et al., Ref 12) 26 3987 15 3981 1.71 (0.91 to 3.21)
Pfizer (Ref 15) 2 285 0 140 2.48 (0.12 to 52.0)
PreSAP (Levin, Ref 17) 9 933 3 628 1.84 (0.54 to 6.28)
Geba et al. (Ref 18) 0 97 0 94 0.97 (0.02 to 49.4)
Pooled 1.88 (1.15 to 3.08)
I-squared statistic 0 (0 to 0)
Cerebrovascular events
Solomon et al. (Ref 6) 8 1356 3 679 1.22 (0.35 to 4.24)
CLASS (White et al. Ref 12) 4 3987 12 3981 0.36 (0.12 to 1.05)
Pfizer (Ref 15) 8 285 5 140 0.75 (0.25 to 2.25)
McKenna et al. (Ref 16) 0 201 2 399 0.39 (0.02 to 8.3)
PreSAP (Levin, Ref 17) 8 933 5 628 1.04 (0.35 to 4.24)
Geba et al. (Ref 18) 0 97 0 94 0.97 (0.02 to 49.4)
Pooled 0.73 (0.42 to 1.26)
I-squared statistic 0 (0 to 56)
Cardiovascular death
Solomon et al. (Ref 6) 9 1356 1 679 4.5 (0.57 to 35.8)
CLASS (White et al. Ref 12) 10 3987 10 3981 0.99 (0.42 to 2.4)
Pfizer (Ref 15) 5 285 2 140 1.23 (0.24 to 6.4)
PreSAP (Levin, Ref 17) 2 933 4 628 0.34 (0.06 to 1.84)
Pooled 1.02 (0.52 to 1.99)
I-squared statistic 18 (0 to 88)
Composite cardiovascular events
Solomon et al. (Ref 6) 49 1356 13 679 1.87 (1.01 to 3.43)
CLASS (White et al., Ref 12) 55 3987 49 3981 1.12 (0.76 to 1.65)
Pfizer (Ref 15) 11 285 5 140 1.03 (0.37 to 2.91)
McKenna et al. (Ref 16) 0 201 2 399 0.39 (0.02 to 8.3)
PreSAP (Levin, Ref 17) 19 933 12 628 1.05 (0.51 to 2.16)
Geba et al. (Ref 18) 0 97 0 94 0.97 (0.02 to 49.4)
Pooled 1.22 (0.92 to 1.62)
I-squared statistic 0 (0 to 56)

McKenna et al. (Ref 16) did not report data on myocardial infarction and cardiovascular deaths. Geba et al. (Ref 18) did not report data on cardiovascular death

See Table 1 for key to additional abbreviations